Early study drug discontinuation due to participant decision (1, 2, 7 and 11), adverse event (3) or non-compliance (6). d Bictegravir plasma concentrations were undetectable at this study visit and BIC/FTC/TAF adherence was 76% by pill count up to week 12. e The NNRTI resistance substitution E138K emerged at week 36, but was not associated with resistance to the current regimen.
. Phenotypic fold change represents the half-maximal inhibitory concentration compared with that of the intra-assay WT control. Fold change values greater than or equal to the assay cut-off indicate resistance. Phenotypic cut-offs are 2.5 for bictegravir, 4.0 for dolutegravir, 4.5 for abacavir, 3.5 for lamivudine, 3.5 for emtricitabine, 1.4 for tenofovir (parent compound of tenofovir alafenamide), 5.2 for boosted atazanavir and 10 for boosted darunavir.
